Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
APL-2, Pegcetacoplan · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Pegcetacoplan, 15 mg/100 μL (single dose), intravitreal injection via prefilled syringe | EXPERIMENTAL | This is a 30-day, phase 3b, single-arm, open-label, multicenter study to evaluate the safety of IVT pegcetacoplan administered via PFS in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The study consists of a screening/baseline visit at day 1, a follow-up call at day 7, and an end of study visit at day 30. |
| Name | Type | Description |
|---|---|---|
| APL-2, Pegcetacoplan | DRUG | Complement (C3) Inhibitor |
Inclusion Criteria: 1. Participants must be aged at least 60 years and have a diagnosis of GA secondary to AMD. 2. Participants must have adequate clarity of ocular media, adequate pupillary dilation, and fixation to permit the collection of good quality images in the study eye as determined by the...
APL-2, also known as pegcetacoplan, is an investigational therapy being studied for paroxysmal nocturnal hemoglobinuria, geographic atrophy, warm autoimmune hemolytic anemia, and IgA nephropathy. It is in Phase 3 clinical development for these conditions.
APL-2 targets the complement system. It is designed to inhibit complement component C3, which plays a role in the immune response. This mechanism is being investigated for conditions like geographic atrophy and paroxysmal nocturnal hemoglobinuria.
APL-2 is being developed by Apellis Pharmaceuticals, Inc., a biopharmaceutical company. The company's stock is traded under the ticker symbol APLS.
APL-2 is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Clinical trials are ongoing to evaluate its safety and efficacy for various indications.
APL-2 has been studied in several Phase 3 trials. These include NCT03525600 and NCT03525613 for geographic atrophy secondary to age-related macular degeneration, NCT04085601 for paroxysmal nocturnal hemoglobinuria, and NCT07214740 for geographic atrophy using a prefilled syringe.
Yes, APL-2 is also known as pegcetacoplan. The drug is referred to by both names in clinical research and development contexts.